Physician profile
Laura Ragna
NPI 1750700357
$5,708.52
in general payments reported to CMS, 2019-2025
33 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.64 · 2020: $42.83 · 2021: $688 · 2022: $1,080 · 2023: $410 · 2024: $1,724 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,811 · Education: $73.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,811.46 |
| Education | $73.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,103.34 | 2022-2025 | |
| Livanova USA, INC. | $708.27 | 2020-2022 | |
| Lundbeck LLC | $247.72 | 2024-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $224.00 | 2022-2025 | |
| Ucb, INC. | $200.98 | 2024-2025 | Rystiggo, Briviact, Nayzilam |
| Merz Pharmaceuticals, LLC | $191.02 | 2024-2025 | Xeomin, Inbrija |
| Pfizer INC. | $184.63 | 2024-2025 | |
| Amgen INC. | $180.20 | 2019-2025 | Uplizna |
| Silk Road Medical, INC. | $170.76 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Astrazeneca Pharmaceuticals LP | $153.11 | 2021-2025 | Wainua |
| Argenx US, INC. | $150.98 | 2023-2025 | Vyvgart |
| Biogen, INC. | $132.19 | 2022-2025 | Vumerity, Tysabri |
| Neurelis, INC. | $111.83 | 2021 | |
| Amneal Pharmaceuticals LLC | $93.11 | 2022-2024 | Rytary |
| Allergan, INC. | $89.26 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $83.77 | 2023-2024 | Aptiom |
| Eisai INC. | $77.94 | 2024-2025 | |
| Sk Life Science, INC. | $75.92 | 2021-2025 | |
| Csl Behring | $60.21 | 2022-2025 | Privigen, Hizentra |
| Lilly USA, LLC | $54.49 | 2024 | Emgality, Amyvid, Kisunla |
| Aucta Pharmaceuticals, INC. | $54.06 | 2024-2025 | Motpoly Xr |
| Vanda Pharmaceuticals INC. | $49.17 | 2024-2025 | Ponvory |
| Tanabe Pharma America, INC. | $39.92 | 2022-2024 | |
| Abbott Laboratories | $39.62 | 2024-2025 | Infinity |
| Jazz Pharmaceuticals INC. | $39.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.63 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $30.16 | 2025 | |
| Acadia Pharmaceuticals INC | $28.24 | 2024 | Daybue |
| Octapharma USA, INC. | $23.97 | 2025 | Panzyga |
| Dendreon Pharmaceuticals LLC | $23.01 | 2020 | |
| Genentech USA, INC. | $22.05 | 2025 | Ocrevus |
| Sunovion Pharmaceuticals INC. | $17.07 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Ragna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.